Cargando…

Interrupting methotrexate to improve immunity after COVID-19 booster vaccination: is it really worth it?

Detalles Bibliográficos
Autores principales:	Jorda, Anselm, Zeitlinger, Markus
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier Ltd. 2022
Materias:	Correspondence
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9428575/ https://www.ncbi.nlm.nih.gov/pubmed/36057280 http://dx.doi.org/10.1016/S2213-2600(22)00271-5

Ejemplares similares

Association between reactogenicity and immunogenicity after BNT162b2 booster vaccination: a secondary analysis of a prospective cohort study
por: Jorda, Anselm, et al.
Publicado: (2023)

Improving COVID-19 vaccine immunogenicity by interrupting methotrexate treatment
por: Sparks, Jeffrey A, et al.
Publicado: (2022)

Effect of hybrid immunity and bivalent booster vaccination on omicron sublineage neutralisation
por: Hoffmann, Markus, et al.
Publicado: (2023)

Booster vaccines for COVID-19 vaccine breakthrough cases?
por: Nixon, Douglas F, et al.
Publicado: (2022)

Withholding methotrexate after COVID-19 vaccination: different strategies, same results?
por: De Medeiros-Ribeiro, Ana C, et al.
Publicado: (2022)

Preclinical Pharmacokinetic/Pharmacodynamic Studies and Clinical Trials in the Drug Development Process of EMA-Approved Antibacterial Agents: A Review
por: Jorda, Anselm, et al.
Publicado: (2020)

Booster vaccines for COVID-19 vaccine breakthrough cases? – Authors' reply
por: Krause, Philip R, et al.
Publicado: (2022)

Withholding methotrexate after COVID-19 vaccination: different strategies, same results? – Author's reply
por: Mehta, Pankti, et al.
Publicado: (2022)

The epidemiological relevance of the COVID-19-vaccinated population is decreasing after booster vaccination, as shown by incidence rate ratios
por: Bohnert, Jürgen A., et al.
Publicado: (2022)

What does 95% COVID-19 vaccine efficacy really mean?
por: Olliaro, Piero
Publicado: (2021)

Reply to Worth et al
por: Mitchell, Brett G., et al.
Publicado: (2014)

COVID-19 booster doses in pregnancy and global vaccine equity
por: Kalafat, Erkan, et al.
Publicado: (2022)

WHO prequalified tocilizumab and vaccine boosters against COVID-19
por: Rahimi, Farid, et al.
Publicado: (2022)

Booster vaccinations protect shipboard personnel from COVID-19
por: Ryan, Margaret, et al.
Publicado: (2022)

Is ipsilateral administration of COVID-19 vaccine boosters the optimal approach?
por: Ziegler, Laura, et al.
Publicado: (2023)

Risk versus reward: is this stock really worth it?
por: Kahn, Michael N, et al.
Publicado: (2011)

Comparison of Waning Immunity Between Booster Vaccination and 2-Dose Vaccination With BNT162b2
por: Jung, Jiwon, et al.
Publicado: (2022)

Is COVID in Neonates Really Mild?
por: Khamkar, Anilkumar M., et al.
Publicado: (2021)

Inhaled budesonide for early treatment of COVID-19
por: Zeitlinger, Markus, et al.
Publicado: (2021)

The epidemiological relevance of the COVID-19-vaccinated population is decreasing after booster vaccination, as shown by incidence rate ratios—author's reply
por: Kampf, Günter
Publicado: (2022)

An Economic Analysis: Is Fidaxomicin Worth the Cost?
por: Shah, Hemal, et al.
Publicado: (2014)

Safety of COVID-19 booster dose: is the juice worth the squeeze?
por: Madhi, Shabir A, et al.
Publicado: (2023)

Do health-care workers need a COVID-19 vaccine booster?
por: Cirillo, Nicola
Publicado: (2022)

Bivalent COVID-19 booster vaccines and the absence of BA.5-specific antibodies
por: Carreño, Juan Manuel, et al.
Publicado: (2023)

Measles Immunization: Worth Considering Containment Strategy for SARS-CoV-2 Global Outbreak
por: Hanker, Varnit S.
Publicado: (2020)

Humoral and cellular responses after COVID-19 booster vaccination in patients recently treated with anti-CD20 antibodies
por: Nishikubo, Masashi, et al.
Publicado: (2023)

Absolute and Relative Vaccine Effectiveness of Primary and Booster Series of COVID-19 Vaccines Against COVID-19 Hospitalizations: Comment
por: Kleebayoon, Amnuay, et al.
Publicado: (2023)

Immunogenicity and Safety of Beta-Adjuvanted Recombinant Booster Vaccine
por: Launay, Odile, et al.
Publicado: (2022)

Antibody response to SARS-CoV-2 WT and Omicron BA.4/5 of inactivated COVID-19 vaccine in patients with lung cancer after second and booster immunization
por: Chen, Chen, et al.
Publicado: (2023)

Heterologous booster response after inactivated virus BBIBP-CorV vaccination in older people
por: Rouco, Santiago Oviedo, et al.
Publicado: (2022)

Hounsfield units in pseudo subarachnoid hemorrhage: worth looking for
por: Senthilkumaran, Subramanian, et al.
Publicado: (2017)

Booster and Btki Interruption Improve Response to Sars-Cov-2 Vaccine in Patients with CLL
por: Bryer, Emily, et al.
Publicado: (2022)

Alopecia areata induced by the booster shot of Sinovac COVID-19 vaccination: a case report
por: Wu, Yi, et al.
Publicado: (2023)

Immunogenicity of BA.5 Bivalent mRNA Vaccine Boosters
por: Collier, Ai-ris Y., et al.
Publicado: (2023)

Extracorporeal Membrane Oxygenation for Critically Ill Patients with COVID-19–related Acute Respiratory Distress Syndrome: Worth the Effort!
por: Wengenmayer, Tobias, et al.
Publicado: (2020)

SARS-CoV-2 Omicron Variant Neutralization after mRNA-1273 Booster Vaccination
por: Pajon, Rolando, et al.
Publicado: (2022)

Does MAFLD really increase the severity of COVID-19?
por: Fajar, Jonny Karunia, et al.
Publicado: (2021)

Anticoagulant Treatment Regimens in Patients With Covid‐19: A Meta‐Analysis
por: Jorda, Anselm, et al.
Publicado: (2021)

Is Fibrosis Really Fibrosis?
por: Vijayakumar, Bavithra, et al.
Publicado: (2021)

Letter from Dr. E. J. B. Ft. Worth
Publicado: (1886)

Cannot write session to /tmp/vufind_sessions/sess_m174konf4h75p5rjesv90hpa01